NYSE$HUM
Humana Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Humana's financial performance in Q2 2021 reflected solid fundamentals, offset by COVID-19 impacts, with GAAP EPS of $4.55 and Adjusted EPS of $6.89.
Humana reported a GAAP EPS of $4.55 and an adjusted EPS of $6.89 for Q2 2021. The company maintains its full-year 2021 adjusted EPS financial guidance and reaffirms its expected individual Medicare Advantage membership growth range.
- Reported 2Q21 earnings per diluted common share of $4.55 on a GAAP basis, $6.89 on an Adjusted basis.
- Updated FY 2021 EPS guidance to a range of $24.97 to $25.47 on a GAAP basis, maintains $21.25 to $21.75 on Adjusted basis.
- Reaffirmed FY 2021 expected individual Medicare Advantage membership growth range of approximately 425,000 to 475,000 members.
- Results reflect solid fundamentals in the company's businesses, offset by continued impacts of the COVID-19 pandemic.
Headline financials
Revenue & EPS history
Humana · Revenue · Quarterly
$20.6B
Revenue by segment
Humana · $18.5B total across 1 segment · Q2 2021
- Insurance$18.5B+9.3%100.0%
Forward guidance
Humana is maintaining its FY 2021 Adjusted EPS guidance range of $21.25 to $21.75, while continuing to acknowledge the heightened uncertainty surrounding the ongoing pandemic as it respects COVID hospitalization trends and the rate at which non-COVID utilization normalizes.
Tailwinds
- The revised GAAP EPS guidance reflects the YTD 2021 impact of the company's non-consolidating minority interest put/call valuation adjustments.
- The revised GAAP EPS guidance reflects the YTD 2021 change in the fair market value of publicly-traded equity securities held by the company.
- The revised GAAP EPS guidance reflects the estimated impact of transaction and integration costs associated with the pending Kindred at Home acquisition.
- The revised GAAP EPS guidance reflects a mark to market gain, currently expected to approximate $1 billion, associated with the company's existing 40 percent minority ownership of Kindred at Home.
- The company’s FY 2021 Adjusted EPS guidance assumes a $600 million COVID related headwind that is expected to be largely offset by favorable operating items.
Headwinds
- Humana is revising its GAAP EPS guidance range for the year ending December 31, 2021 (FY 2021) to $24.97 to $25.47 from the previous range of $19.62 to $20.12.
- The company continues to acknowledge the heightened uncertainty surrounding the ongoing pandemic as it respects COVID hospitalization trends and the rate at which non-COVID utilization normalizes.
- The FY 2021 Adjusted EPS guidance assumes non-COVID utilization will run 2.5 percent below baseline in the back half of the year.
- The FY 2021 Adjusted EPS guidance includes an assumption of minimal COVID testing and treatment costs for the remainder of the year.
- The spread of, and response to, the novel coronavirus, or COVID-19, underscores certain risks Humana faces.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
+0.9%
Avg return
Earnings day
+0.5%
Avg return
5 days after
+2.8%
Avg return
30 days after
62%
45 / 73 earnings
Positive
+12.4%
Q2 2025
Best reaction
-12.6%
Q2 2012
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +5.5% | +3.6% | +33.3% | |
| Q4 2025 | -3.3% | +1.5% | -8.8% | |
| Q3 2025 | -6.0% | -15.4% | -8.5% | |
| Q2 2025 | +12.4% | +6.3% | +30.5% | |
| Q1 2025 | +1.1% | -1.0% | -10.1% | |
| Q4 2024 | -3.5% | -4.9% | -5.6% | |
| Q3 2024 | +0.0% | -0.9% | +15.0% | |
| Q2 2024 | -11.3% | -11.9% | -12.4% | |
| Q1 2024 | -5.1% | -7.6% | +6.5% | |
| Q4 2023 | -10.2% | -6.4% | -9.8% | |
| Q3 2023 | -8.1% | -6.9% | -5.4% | |
| Q2 2023 | +6.3% | +8.0% | +0.5% | |
| Q1 2023 | +4.7% | +6.7% | -1.0% | |
| Q4 2022 | -4.3% | -5.0% | -2.2% | |
| Q3 2022 | +1.5% | +0.1% | -1.4% | |
| Q2 2022 | -1.7% | -3.6% | -1.1% | |
| Q1 2022 | +6.6% | +0.7% | +7.1% | |
| Q4 2021 | +9.1% | +10.2% | +13.0% | |
| Q3 2021 | -0.8% | -0.6% | -7.7% | |
| Q2 2021 | -7.9% | -8.1% | -13.2% | |
| Q1 2021 | -0.3% | +0.4% | -2.5% | |
| Q4 2020 | +2.1% | +0.4% | +5.9% | |
| Q3 2020 | +10.6% | +5.9% | -1.2% | |
| Q2 2020 | +4.2% | +7.3% | +5.6% | |
| Q1 2020 | +5.2% | +4.1% | +13.2% | |
| Q4 2019 | +4.8% | +3.0% | +7.1% | |
| Q3 2019 | +6.9% | +7.7% | +18.1% | |
| Q2 2019 | +4.8% | +0.8% | -0.5% | |
| Q1 2019 | -3.1% | -2.3% | -4.1% | |
| Q4 2018 | +0.2% | -3.2% | -11.6% | |
| Q3 2018 | +2.3% | +1.8% | -7.8% | |
| Q2 2018 | +2.4% | +2.8% | +6.1% | |
| Q1 2018 | -2.9% | -3.9% | -1.9% | |
| Q4 2017 | -2.5% | -0.8% | +1.3% | |
| Q3 2017 | -3.5% | -6.0% | +0.1% | |
| Q2 2017 | +7.8% | +8.2% | +12.1% | |
| Q1 2017 | +2.0% | +3.9% | +8.4% | |
| Q4 2016 | +6.0% | +5.9% | +11.6% | |
| Q3 2016 | +5.8% | +12.5% | +29.2% | |
| Q2 2016 | +2.5% | +4.8% | +4.6% | |
| Q1 2016 | -1.6% | — | — | |
| Q4 2015 | -0.9% | — | — | |
| Q3 2015 | -0.8% | — | — | |
| Q2 2015 | -0.4% | — | — | |
| Q1 2015 | -8.6% | — | — | |
| Q4 2014 | +1.2% | — | — | |
| Q3 2014 | -5.3% | — | — | |
| Q2 2014 | -7.7% | — | — | |
| Q1 2014 | +6.3% | — | — | |
| Q4 2013 | -0.8% | — | — | |
| Q3 2013 | +1.6% | — | — | |
| Q2 2013 | +2.3% | — | — | |
| Q1 2013 | +1.6% | — | — | |
| Q4 2012 | +7.0% | — | — | |
| Q3 2012 | +1.3% | — | — | |
| Q2 2012 | -12.6% | — | — | |
| Q1 2012 | -4.0% | — | — | |
| Q4 2011 | +1.0% | — | — | |
| Q3 2011 | +4.2% | — | — | |
| Q2 2011 | -2.0% | — | — | |
| Q1 2011 | +1.8% | — | — | |
| Q4 2010 | +3.5% | — | — | |
| Q3 2010 | +4.0% | — | — | |
| Q2 2010 | +4.0% | — | — | |
| Q1 2009 | +4.9% | — | — | |
| Q1 2010 | -0.9% | — | — | |
| Q4 2009 | +3.6% | — | — | |
| Q4 2007 | +3.6% | — | — | |
| Q3 2008 | +5.0% | — | — | |
| Q3 2009 | +5.0% | — | — | |
| Q4 2008 | +2.0% | — | — | |
| Q2 2009 | +2.0% | — | — | |
| Q2 2008 | +2.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro